Last checked at 27 May 2010 07:00
| For immediate release | 27 May 2010 |
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
AGM Statement
Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, will hold its Annual General Meeting in London later this morning.
Michael Gatenby, the Company's Chairman, will make the following comments:
"I am pleased to report that trading in the first four months of 2010 has been ahead of our expectations and significantly ahead of last year. Alliance continues to benefit from the positive sales trends reported at the time of the Company's preliminary results.
"Turnover in the four month period ended 30 April 2010 was £15.0 million, 88% higher than the same period in 2009. This four month period includes £2.7 million of sales from the products acquired from Cambridge Laboratories in February 2010 and from Reckitt Benckiser in August 2009.
"Sales of Deltacortril® / enteric coated prednisolone tablets continue to be strong. We remain cautious that the prednisolone market may become more competitive over time, though this has not happened to date.
"The Cambridge Laboratories acquisition has been successfully integrated into Alliance ahead of schedule. Sales by Alliance of the Cambridge Laboratories products in the first 10 weeks post-acquisition have been in line with our expectations.
"We look forward to the remainder of 2010 with confidence."
For further information:
Alliance Pharma plc | + 44 (0) 1249 466966 |
| John Dawson, Chief Executive |
|
| Richard Wright, Finance Director |
|
| www.alliancepharma.co.uk |
|
|
|
|
Buchanan Communications | + 44 (0) 20 7466 5000 |
| Mark Court / Stasa Filiplic |
|
|
|
|
| Numis Securities Limited | + 44 (0) 20 7260 1000 |
| Nominated Adviser: Michael Meade / Brent Nabbs |
|
| Corporate Broking: David Poutney |
|
Notes to editors:
About Alliance
Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and owns or licenses the rights to more than 50 pharmaceutical products and continues to explore opportunities to expand the range.
Alliance's products are prescribed in the treatment of a wide range of conditions and include products used in the treatment of dermatological conditions, in oncology, in childbirth, in the prevention of heart disease, in Parkinson's disease, in nutrition and in nasal infections. Alliance's sales are mainly prescription driven. Its products are distributed both to hospitals directly and to pharmaceutical wholesalers, which in turn service both hospital and retail pharmacies with their prescription requirements.
Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.